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INTRODUCTION
Transcriptional control of gene expression is intimately linked to the post-translational modification of chromatin by acetylation, methylation or phosphorylation. Further, acetylation status of the chromatin has been shown to have fundamental importance in the initiation or progression of cancer. Acetylation status of the chromatin, modulated by histone acetylases (HATs) and histone deacetylases (HDACs), is responsible for chromatin remodeling that is required for gene expression (1-3). HATs acetylate histones at the lysine residues thus neutralizing the charge (2, 4) . The resulting relaxation of the nucleosomal core particle leads to transcriptional activation (5, 6) . HDACs on the other hand, remove acetyl groups from acetylated histones leading to chromatin compaction and transcriptional repression (5) (6) (7) . HDACs have been shown to target not only histones but several other transcription factors like RB, p53, NFκB, ATM and MEF2 for deacetylation (7) .
Since, aberrant activity of HDACs leads to the transcriptional repression of tumor suppressor genes contributing to tumor formation (7) , targeting of HDACs with inhibitors would not only disrupt normal transcriptional regulation of specific genes through the relaxation of chromatin conformation but also can be used as a cancer therapy approach. Indeed, several types of HDAC inhibitors have been shown to have antitumor activities in both tumor cells and xenografted models (8) (9) (10) (11) (12) (13) . Due to the success of HDAC inhibitors in preclinical studies, Phase I and II clinical trials of several different inhibitors have been initiated (14) (15) (16) (17) . In addition to anti-tumor activity, HDAC inhibitors have shown several biological effects-morphological changes (18), transcriptional changes (19, 20) , cell differentiation (21) , cell cycle arrest (22, 23) , antiangiogenesis (24) and apoptosis (23, (25) (26) (27) (reviewed in (6) ).
Several distinct classes of HDAC inhibitors have been reported including short chain fatty acids (28, 29) , benzamide derivatives (30) , trichostatin and analogues (31, 32) , hybrid polar compounds (33) , cyclic tetrapeptides (34, 35) and the depsipeptide (36) . Among these, short chain fatty acids are least potent and their efficacy has been limited by low antiproliferative activity, rapid metabolism and non-specific mode of action (37) . Based on the X-ray crystallographic structure of HDAC enzyme, Zn 2+ -chelating, motif-tethered, short chain fatty acids were developed as novel class of HDAC inhibitors (37) . Two of these inhibitors (VAD-18 and VAD-20) having phenylacetic acid and butyric acid respectively as the lead compound ( Fig. 1 ) have been used in the present study. Since, these inhibitors have aromatic chain (rather than aliphatic chain present in most other inhibitors) as the linker between the lead compound and Zn 2+ chelating hydroxamic acid, there is more strong interaction between the hydrophobic pocket of the active site of the enzyme and the inhibitor thus increasing the potency of inhibition (37) . Indeed, these inhibitors alone showed upregulation of p21 WAF/CIP1 expression and hyper-acetylation of histones H-3 and H-4 in DU-145 cells at concentrations significantly lower than the parent molecule phenylbutyrate (37).
Lu et al (38) further embarked on the structure-based optimization of these inhibitors by using the framework generated by the crystal structure of histone deacetylase-like protein (HDLP)-TSA complexes.
Based on the hypothesis that the hydrophobic residues flanking the cap group-binding motif could be exploited 5 for lead optimization, they generated (S)-11 ((S)-HDAC-42), an optically active α-branched phenylbutyryl derivative, with IC 50 of 16 nM in HDAC inhibition (Fig. 2) . (S)-HDAC-42 also showed hyper-acetylation of H3 in PC-3 cells (39) . Statement of work for the proposal was therefore modified and VADs were replaced with (S)-HDAC-42, a second generation inhibitor. The effects of this inhibitor in combination with radiation will be compared with SAHA. b. Perform TUNEL assay and flow cytometric measurements of DNA content for studying the HDAC inhibitors-induced apoptosis in the presence or absence of radiation.
HDAC inhibitors inhibit HDAC enzymes leading to hyper-acetylation of the chromatin and thus affecting the transcription of several genes. Inhibition of the radiation-induced pro-survival genes by these inhibitors and simultaneous induction of pro-apoptotic genes irrespective of androgen functional status will dominantly lead to enhanced cell death. Thus, we studied the cell death in presence of these inhibitors with and without irradiation in these cells. Clonogenic survival and apoptosis of these cell lines in the presence of HDAC inhibitors alone or in combination with ionizing radiation treatment was determined by colony forming assay and flow cytometry (sub G 0 /G 1 population).
Task 1 a: PC-3 cells were treated with various concentrations of VAD-18 and VAD-20 to find the IC 50 concentration for each drug. The decrease in surviving fraction with increasing concentration was observed with both the drugs (Fig. 3 a) . However, VAD-18 was more cytotoxic than VAD-20 with the corresponding IC 50 concentrations of 0.5 µM and 7.5 µM. The effects of VAD-18 (0.5 µM) and VAD-20 (7.5 µM) in combination with radiation (1-6 Gy) on survival of PC-3 cells are presented in Fig. 3b . Colony forming assays showed significant radio-sensitizing effects with both the inhibitors at IC 50 IC 50 concentrations of (S)-HDAC-42 and SAHA were calculated using clonogenic survival assay in PC-3, LN-3 and DU-145 cells. LN-3 cells (p53 wild type; partially androgen-dependent) were slightly more sensitive to both (S)-HDAC-42 and SAHA compared to DU-145 (p53 mutated; androgen-independent) and PC-3 (p53 null; androgen-independent) cells (Fig. 4 a and b ; Table 2 ). Radiosensitizing effects of (S)-HDAC-42 and SAHA were investigated in PC-3 and DU145 cells using colony forming assays (Fig. 4 c and d following treatment of cells with either of the drugs till 24 h. However, at later time points (after 24-72 h), the block was released. To investigate whether sustained arrest in G 2 /M phase could be observed, cell cycle distribution studies were performed with higher concentrations of VAD-18 (0.5 to 1 µM) and VAD-20 (7.5 to 15 µM). However, similar results were obtained as with IC 50 concentrations (data not shown). Since, the hypodiploid peak was apparent only at 36 h and later, it appears that only delayed apoptosis was enhanced in combined treatment as cells blocked in G 2 /M harbor more damage, which could lead either into apoptosis at a later time or manifest enhanced cytogenetic damage after the release of G 2 /M block and lead to secondary apoptosis. Indeed, analysis of cells by fluorescence microscopy showed enhanced cytogenetic damage with radiation and the combination (data not shown).
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Task 2.
To understand the signaling pathways induced by combined exposures to HDAC inhibitors and ionizing radiation in both androgen dependent and independent prostate cancer cell lines. In particular, effects on pro-survival events will be assessed by analyzing androgen receptor-mediated and NFkappaB-mediated signaling pathways. Further, pro-apoptotic effectors such as Bax induction, cytochrome C release and caspase activity will be assessed in response to this combined treatment.
a. Perform Western blot analyses for quantifying the levels of NFkappaB sub-units (p65 and p50), IkappaBalpha, p-IkappaB-alpha, Bax, Bcl-2, Bcl-XL, cytochrome C, p21, AR protein, PI-3 kinase, AKT, phospho-AKT, PTEN following the combined treatment either in whole cell lysates or cytosolic and nuclear extracts.
b. Perform electrophoretic mobility shift assays (EMSA) and reporter assays (using 3x kappaB-Luc and ARLuc) for assessing the transactivation activity of NFkappaB. 10 status will dominantly lead to enhanced cell death. Thus, we studied the expression and function of different proteins responsible for either survival or death of cells in presence of these inhibitors with and without radiation using Western blot analysis in PC-3 cells.
Expressions of p65 (one of the components of NFκB, a survival protein) and pro-apoptotic protein (Bax) and anti-apoptotic proteins (Bcl XL and Bcl 2 ) following treatment with HDAC inhibitors and radiation (2 Gy) were analyzed by Western blot analysis in either cytosolic or nuclear fractions. While, with all the treatments, p65 protein was present in the nuclear extract 1 h post-treatment, its expression decreased at 3 h and again an increase was observed from 6 h post-treatment except in V20 and V20+IR group (Fig. 6 a) . This second appearance of p65 in the nucleus was more with IR alone. These time dependent changes in p65 localization and therefore its activity were further confirmed with immunofluorescence and gel shift assays and are described below. Since, the combination treatment resulted in less total p65 in the nucleus compared to 2 Gy treatment, this implies that the inhibitors may sensitize the cells to IR by reducing the levels of IR-induced p65 translocation in the nucleus (Fig. 6 a) . Consistent with the presence of p65 in the nucleus, levels of anti-apoptotic protein, Bcl XL , a target of p65 increased from 30 min to 6 h post-treatment in all the groups except V20+2Gy, where the levels were consistently reduced from 30 min to 24 h post-treatment (Fig. 6 b) . Expression of Bcl XL was however reduced in all the groups compared to untreated group at 12 and 24 h post treatment time (Fig. 6 b) . Levels of Bcl 2 ,
another anti-apoptotic member of Bcl 2 family of proteins, remained almost unchanged except for V20+IR group where the levels were significantly reduced compared to untreated group (Fig. 6 c) . Time-dependent changes in the expression of pro-apoptotic Bax protein are shown in Fig. 6 d. Significant increase in the levels was observed only after 12 h of treatment in all the groups except V20+IR. Since, the ratio of pro-to anti-apoptotic proteins determines the response, the enhanced cell death observed in combination treatment groups especially with combination of VAD-20 and radiation could be due to an increase in this ratio.
Since, most of the HDAC inhibitors have been shown to increase the levels of p21 protein (responsible for blocking the cells in G 1 phase of the cell cycle), expression of p21 protein was investigated in PC-3 cells (Fig. 6 e) . Consistent with the cell cycle distribution data, significant increase in the levels of p21 was observed only after 24 h of treatment. This delayed induction of p21 may also be responsible for G 2 /M block of the cells.
Task 2 b:
Electrophoretic mobility gel shift assay: To confirm that p65 is able to bind to its target after localization in to the nucleus, electrophoretic mobility gel shift assay (EMSA) was performed in PC-3 cells. An increase in p65 binding was observed with either the drugs alone or radiation alone at 1 h but the binding was reduced at 3 h followed by an increase again from 6 h post-treatment (Fig. 7) . VAD-20 in combination with 2 Table 1 , VAD-20 has more radiosensitizing effects than VAD-18 in PC-3 cells, which could be due to reduced activity of p65 and enhanced expression of pro-apoptotic proteins with simultaneous reduction in antiapoptotic protein levels shown in Fig. 6 .
Chromatin immuno-precipitation (CHIP) assay:
To confirm the results obtained from EMSA, CHIP assay was carried out in PC-3 cells using Bcl 2 primers (Bcl 2 as target of p65) followed by hot PCR. Results were normalized with 28SrDNA as the control. Similar to the results obtained from EMSA, enhanced binding of p65 to its target promoter (Bcl 2 ) was observed by CHIP analysis only after 6 h of treatment leading to increased transactivation activity.
Task 2 c: Immunofluorescence studies:
To confirm the time dependent changes observed in the localization and activity of p65, immunofluorescence studies were carried out for p65 and its binding partner p50 in PC-3 cells (Fig. 8) . Results obtained from these localization studies reflected the similar pattern. While, p65 and p50 co-localized in the cytoplasm in the control groups, in all the other groups except 5 Gy radiation (co-localization in the nucleus), time dependent changes were observed. The summary of the localization is provided in the table 4 . Most importantly, as observed before, V-20 either alone or in combination with radiation showed colocalization of p65 and p50 in the cytoplasm at 3 and 6 h post-treatment time consistent with the observation with Western analysis, EMSA and CHIP analysis. Table 4 : Effects of VAD-18 (0.5 µM) and VAD-20 (7.5 µM) with radiation (2 or 5 Gy) on the co-localization of p50 and p65 proteins in PC-3 cells. C-cytoplasm; N-nuclear; PN-perinuclear.
Treatment UT 2 Gy 5 Gy V-18 V-20 V-18+2 Gy V-20+2 Gy V-18+5 Gy V-20+5 Gy
Since, results obtained from this task showed that pro-survival protein, p65 may be active at certain time points following treatment, there was a need to look for the other transcription factors responsible for increased response in the form of clonogenic inhibition in PC-3 cells. It has been reported before that the duration of the NFκB nuclear activation depends on the activity of HDAC3, which provides an acetylation balance dependent mechanism for the regulation of NFκB-mediated transcription (46) . Once acetylated active NFκB dimers are present in the nucleus and they will bind to the chromatin at the newly exposed binding sites. Saccani (Table 5) .
Although, USFs are shown to be highly versatile stress responsive transcription factors (51) , their role in ionizing radiation mediated effects has not been studied till now as per our knowledge. Therefore, it was of great interest to investigate the effects of HDAC inhibitors and radiation on the various targets of this transcription factor.
14 Table 5 : TranSignal protein/DNA array (from Panomics) was carried out according to the manufacturer's instructions in PC-3 cells 24 h after the treatment. Results are presented compared to the controls. "Up" stands for up-regulated and "D" for down-regulated transactivation activity of various transcription factors compared to the untreated group; "In"-Induced when basal levels were not present in the control group and "R"-repressed that is transactivation function was absent in the treated group but was present in the control group. In the groups where significant changes were not observed compared to controls, the cell is left blank. We identified four targets of USF-1 which are involved in cellular proliferation and cell cycle; human telomerase reverse transcriptase (hTERT), IGF2R, Cyclin B1 and Cdk1. Since, USF-1 transactivation function was found to be down-regulated following HDAC inhibitor treatments by protein/DNA array in PC-3 cells, we expected that expression of its target proteins, which are found to be associated with carcinogenesis or proliferation should also be reduced. To confirm this hypothesis, we performed real time RT PCR with the primers from Applied Biosystems. Results are presented in Fig. 9 .
An induction in gene expression was observed following irradiation of cells with 5 Gy dose for all the four genes. All the other treatment groups however, showed reduction in the expression as expected. Thus, the HDAC inhibitors were able to reduce the expression of radiation-induced genes involved in cell proliferation and cell cycle.
Task 3.
To determine the combined effects of HDAC inhibitors plus ionizing radiation on the regression of (i) prostate cancer xenografts (PC-3) in nude mice and (ii) in-situ prostate tumor in TRAMP mice.
a. Implant tumors (PC-3) in nude mice and study the effects of the inhibitors with or without ionizing radiation on tumor growth and animal survival. Following various treatments in PC-3 cells, RNA was extracted and cDNA was prepared using PCR with 1 µg of RNA. Real time PCR was then performed using Applied Biosystems' primers, reagents and instrument. Results are presented after normalization with untreated group and using β actin as the endogenous control.
b.
Study the effects of HDAC inhibitors in combination with ionizing radiation on in-situ tumors in TRAMP mice and follow the regression of the tumor by ultrasound imaging.
To translate the results obtained in cell lines to clinics, it is essential to study the effects of these inhibitors in combination with radiation in tumor bearing animals. We hypothesized that HDAC inhibitors in combination with radiation will inhibit pro-survival gene activity (NFκB and Bcl-2) and upregulate pro-apoptotic events (Bax) and this signaling will enhance the regression of prostate tumor xenografts. In a more basic research setting, the response to treatment can be hard to study because much of the available research material such as cell lines PC-3, LN3 or explants derived from clinical specimens often represent more advanced stage disease.
Tumor xenograft model is one of long-standing pre-clinical screening model to set the stage for clinical trials.
However, they do not closely mimic in-situ tumor situation. In-situ tumor model such as "Transgenic Adenocarcinoma of Mouse Prostate (TRAMP)" has been extensively used in understanding the prostate tumor biology. Growth and development of the prostate glands in the TRAMP mice occurs normally until rising circulating levels of androgen direct the prostate specific probasin regulated transgene to express the SV40 early genes (T/t antigens) thereby initiating the transformation process (52) . Currently, numerous investigators around the world are using the TRAMP model to study various chemoprevention strategies, including dietary and hormonal manipulation, on the timing, incidence and nature of spontaneous prostate cancer. Furthermore, because the TRAMP mice were generated in the pure C57BL/6 background, they have an intact immune system and thereby facilitate studies designed to exploit the immune response in vaccine based prevention studies, a clear advantage over other "in vivo" models that require the use of immunodeficient nude mouse hosts.
Breeding and genotyping:
To perform these experiments, we are currently breeding in house TRAMP (transgenic adenocarcinoma mouse prostate) mouse (C57BL/6 x FVB PB-Tag transgene mouse) colony from heterozygous males and females received from Dr Greenberg, Baylor College, Texas. Genotyping of these mice was performed after extracting DNA from the ear punch samples and performing PCR. The crossbreeding data are given in Table 6 . We have obtained 16 true TRAMPs till now; 8 male and 8 females. These are being further bred to generate more TRAMP mice. does not have MRI facility, we plan to do the imaging using ultrasound that is available in the animal facility of the Center with the help of urologists. These prostate images will be used for volumetric measurements and treatment planning for radiation.
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Ultrasound images will be acquired on day 0 when tumors reach tumor volume of ~5 mm 3 , day 5, day 10, day 15, day 20, day 25 and day 30. Volumes will be calculated from these images and regression will be analyzed. The following method will be used for imaging:
Ultrasound imaging methods: Transabdominal ultrasound using 15.0 MHz UltraBand linear transducer (Agilent SONOS 5500, Andover, Massachusetts) will be performed in TRAMP mice. Before ultrasound, the mice will be anesthetized with isoflurane (3% in room air) and the abdomen will be shaved. The volume of the tumor will be estimated using the following formula: length x width x depth x 0.5. This measure has been shown to correlate well with actual tumor size in mice (53) . Additional images will be acquired to characterize the tumor's progression. Contours of the identified tumors/prostate will be identified. Volume information will then be extracted utilizing the Dose Volume Histogram (DVH). Temporal tumor volume studies will be achieved by imaging sessions that precede each irradiation time.
For irradiation of tumors in either xenografts or TRAMP mice we proposed to use Cs-137 gamma irradiator. In Weis Center for Research we have two X-ray superficial units (Bucky X-Ray International, Inc.
and Therapax 150T, Oldelft Corporation) located in the animal house itself and we plan to irradiate tumors with X-rays rather than gamma rays as proposed in specific aim 3. This should not affect the aim as X-rays are more close to clinical situation where they are used for treatment more frequently than gamma rays.
Administration of radiation therapy:
The tumors will be irradiated locally at room temperature by a X-ray superficial unit. The current dose rate is 3.0 Gy/min at the center of the tumor. A uniform dose (± 2%) can be obtained in the center of an 8 cm length. For in-situ TRAMP tumors, 0.5 cm cons will be placed on the lower abdominal area to irradiate the in-situ prostate tumor by specific target alignment. Determination of tumor growth and survival will be made. Statistical significance of differences in survival will be assessed by the method of Kaplan-Meier.
III. KEY RESEARCH ACCOMPLISHMENTS
• VAD-18, VAD-20 and (S)-HDAC-42 are novel HDAC inhibitors that require low doses to modulate hyper-acetylation mediated effects.
• HDAC inhibitors are potential radio-sensitizers in vitro.
• Effects of these inhibitors are mediated through cell cycle arrest, down-regulation of anti-apoptotic proteins, upregulation of pro-apoptotic proteins and abrogation of radiation-induced nuclear translocation of p65, thereby, enhancing cell death.
• A novel signaling pathway is identified in which the effects of HDAC inhibitors are mediated through USF-1 transcription factor. Since, till date role of USF-1 in IR-induced effects are not identified, it will be of great importance to dissect this pathway completely.
• Established EMSA protocol to assess the p65 transactivation function in cells treated with HDAC inhibitors and radiation therapy (method accomplishment).
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• MRI based imaging of mouse prostate was established (Imaging Protocol accomplishment). However, in
Weis Center of Research, ultrasound imaging will be used instead.
• Established external beam radiation treatment planning protocol to irradiate mouse prostate tumors. In
Weis Center for Research, superficial X-ray unit will be used to irradiate tumors.
IV. REPORTABLE OUTCOMES
Since the granting period, we have presented the results in three conferences and we are in progress for completing a manuscript for publication. These reportable outcomes were pertaining to the findings of specific 
Manuscript in preparation
• Seema Gupta, Ching-Shih Chen, Mansoor M. Ahmed. Radiosensitization of human prostate cancer cell lines by novel histone deacetylase inhibitors.
V. CONCLUSIONS
The major conclusion of specific aims 1 and 2 demonstrated that HDAC inhibitors can radiosensitize tumor cells. Studies in PC-3 cells demonstrate that these effects are mediated through cell cycle distribution changes, abrogation of translocation of p65 to the nucleus and inhibition of its binding activity. Identification of USF-1 transcription factor by protein/DNA array and real time RT PCR has opened a new avenue for dissecting the signaling pathways induced by HDAC inhibitors leading to radiosensitization effects. However, mechanisms of radio-sensitization and differential effects in normal cells remain to be elucidated completely, 20 which will help in synthesizing better inhibitors for improving the radiotherapy of cancer. Studies are in progress:
• To understand the role of USF-1 in the radiosensitizing effects of novel HDAC inhibitors:
expression, binding, activity, translocation etc as well as by intervention studies.
• To investigate radiosensitizing effects of second generation HDAC inhibitor, (S)-HDAC-42 and to compare the results with SAHA in CWR22RV1 and LnCAP cells.
• To study the radiosensitizing effects of these inhibitors in prostate cancer bearing nude mice and TRAMP mice.
VI.
